Arrestins in Bone - Progress in Molecular Biology and Translational Science - page 345

23. Costa T, Herz A. Antagonists with negative intrinsic activity at delta opioid receptors
coupled to GTP-binding proteins. Proc Natl Acad Sci USA . 1989;86(19):7321- 7325.
24. Samama P, Cotecchia S, Costa T, Lefkowitz RJ. A mutation-induced activated state of
the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem .
1993;268:4625 - 4636.
25. Weiss JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-
occupancy model. III. Resurrecting efficacy. J Theor Biol . 1996;181:381 - 397.
26. Maudsley S, Martin B, Luttrell LM. The origins of diversity and specificity in G protein-
coupled receptor signaling. J Pharmacol Exp Ther . 2005;314:485- 494.
27. Laugwitz KL, Allgeier A, Offermanns S, et al. The human thyrotropin receptor: a hep-
tahelical receptor capable of stimulating members of all four G protein families. Proc Natl
Acad Sci USA . 1996;93:116 - 120.
28. Angers S, Salahpour A, Joly E, et al. Detection of beta 2-adrenergic receptor dimeriza-
tion in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl
Acad Sci USA . 2000;97:3684 - 3689.
29. Hay DL, Poyner DR, Sexton PM. GPCR modulation by RAMPs. Pharmacol Ther .
2006;109:173- 197.
30. Foord SM, Marshall FH. RAMPs: accessory proteins for seven transmembrane domain
receptors. Trends Pharmacol Sci . 1999;20:184 - 187.
31. Brady AE, Limbird LE. G protein-coupled receptor interacting proteins: emerging roles
in localization and signal transduction. Cell Signal . 2002;14:297 - 309.
32. Hall RA, Lefkowitz RJ. Regulation of G protein-coupled receptor signaling by scaffold
proteins. Circ Res . 2002;91:672 - 680.
33. Bockaert J, Marin P, Dumuis A, Fagni L. The 'magic tail' of G protein-coupled recep-
tors: an anchorage for functional protein networks. FEBS Lett . 2003;546:65- 72.
34. Luttrell LM, Gesty-Palmer D. Beyond desensitization: physiological relevance of
arrestin-dependent signaling. Pharmacol Rev . 2010;62:305 - 330.
35. Galandrin S, Bouvier M. Distinct signaling profiles of beta1 and beta2 adrenergic recep-
tor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the
pluridimensionality of efficacy. Mol Pharmacol . 2006;70:1575 - 1584.
36. Kenakin T. Agonist-receptor efficacy II: agonist trafficking of receptor signals. Trends
Pharmacol Sci . 1995;16:232 - 238.
37. Wisler JW, DeWire SM, Whalen EJ, et al. A unique mechanism of beta-blocker action:
carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci USA . 2007;104:
16657 - 16662.
38. Bisello A, Chorev M, Rosenblatt M, Monticelli L, Mierke DF, Ferrari SL. Selective
ligand-induced stabilization of active and desensitized parathyroid hormone type 1
receptor conformations. J Biol Chem . 2002;277:38524- 38530.
39. Bisello A, Manen D, Pierroz DD, Usdin TB, Rizzoli R, Ferrari SL. Agonist-specific
regulation of parathyroid hormone (PTH) receptor type 2 activity: structural and func-
tional analysis of PTH- and tuberoinfundibular peptide (TIP) 39-stimulated desensitiza-
tion and internalization. Mol Endocrinol . 2004;18:1486 - 1498.
40. Jouishomme H, Whitfield JF, Chakravarthy B, et al. The protein kinase-C activation
domain of the parathyroid hormone. Endocrinology . 1992;130:53 - 60.
41. Azarani A, Goltzman D, Orlowski J. Structurally diverse N-terminal peptides of para-
thyroid hormone (PTH) and PTH-related peptide (PTHRP) inhibit the Na þ

exchanger NHE3 isoform by binding to the PTH/PTHRP receptor type I and activat-
ing distinct signaling pathways. J Biol Chem . 1996;271:14931- 14936.
42. Takasu H, Gardella TJ, Luck MD, Potts JT, Bringhurst FR. Amino-terminal modifica-
tions of human parathyroid hormone (PTH) selectively alter phospholipase C signaling
via the type 1 PTH receptor: implications for design of signal-specific PTH ligands. Bio-
chemistry . 1999;38:13453 - 13460.

þ /H